AstraZeneca Targets Year-End Filing for Novel Hypertension Drug Baxdrostat
AstraZeneca plans to submit baxdrostat for regulatory review by the end of 2025, aiming for potential approvals in 2026 starting in the U.S. and EU. Baxdrostat inhibits aldosterone, tackling a hormonal driver of hypertension rather than just symptoms.
In advanced trial results presented at a medical meeting, 2 mg baxdrostat added to standard therapy cut systolic BP by 9.8 mmHg (placebo-adjusted) at 12 weeks; 1 mg cut 8.7 mmHg. Investigators noted hyperkalaemia in ~1.1% of patients. AstraZeneca estimates >$5B peak sales, while rival lorundrostat (Mineralys) recently showed a 9.1 mmHg reduction at six weeks. Unmet need in resistant hypertension remains high worldwide.
You May Interested In
SS-31 Cosmetic peptides, discounted price improving cognitive impairment factory supply
$8E+1/UNIT FOB
2026-09-11
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Evonik and AMSilk Expand Collaboration to Develop Sustainable Biotech Silk Materials
-
BASF and Clariant Exit Quietly! Behind Henkel’s High-Priced Acquisition, Why Did Former Allies Choose to “Let Go”?
-
INEOS Inovyn Moths Methyl Chlorocarbonate Production Facility in Tavaux, France
-
Beiersdorf Launches Eucerin Skincare Brand in Japan
-
Henkel's Acquisition of Stahl Enters Regulatory Countdown: Will the €2.1 Billion Deal Go Through?
-
The Pill That Could Swallow the Needle: Novo Nordisk Launches Oral Wegovy in U.S. Weight-Loss Revolution
-
From Desert Sands to Dining Tables: Arab Food & Beverage Sector Emerges as Investment Powerhouse
-
Korea’s Petrochemical Pivot: Industry Embraces Historic Restructuring to Slash Overcapacity
-
Dafeng Haijianuo’s RMB 246 Million Technical Revamp Project Takes Shape, with Multiple Production Lines for Vitamin K1, Folic Acid, and Others Under Construction
-
LANXESS Expands Rubber Additives Production at Qingdao Plant
Recommend Reading
-
![BASF and Encina Bet on Circular Chemical Feedstocks]()
BASF and Encina Bet on Circular Chemical Feedstocks
-
![Kuraray Exits China’s PMMA Market, with Jiangsu Shuangxiang Group Taking Over]()
Kuraray Exits China’s PMMA Market, with Jiangsu Shuangxiang Group Taking Over
-
![BASF Partners with Sinopec to Accelerate Application of Biomethane at Nanjing]()
BASF Partners with Sinopec to Accelerate Application of Biomethane at Nanjing
-
![Lilly’s U.S. API Investment Highlights a New Phase of Pharma Supply Localization]()
Lilly’s U.S. API Investment Highlights a New Phase of Pharma Supply Localization
-
![China’s Agrochemical Role Expands as Global Supply Risks Intensify]()
China’s Agrochemical Role Expands as Global Supply Risks Intensify
-
![Premium Global Chemical Sourcing Requests (20-23Aug, 2026)]()
Premium Global Chemical Sourcing Requests (20-23Aug, 2026)
-
![June 8th: Shandong Asphalt Supply Declines, Market Continues to Rise]()
June 8th: Shandong Asphalt Supply Declines, Market Continues to Rise
-
![Supply Pressure Doubles, Hydrogen Peroxide Prices Continue to Fall in China]()
Supply Pressure Doubles, Hydrogen Peroxide Prices Continue to Fall in China
-
![Business Society’s PTA Market Outlook on August 13, 2026: Volatile]()
Business Society’s PTA Market Outlook on August 13, 2026: Volatile
-
![Moving Average Crossover, June Isooctanol Prices in China Rise]()
Moving Average Crossover, June Isooctanol Prices in China Rise
